Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Formerly part of Thomson Reuters, Clarivate became an independent company in 2016 and went public on the New York Stock Exchange in 2019. The company is headquartered in London with operations in over 100 countries and a workforce of over 4,000 employees.
Clarivate serves a diverse clientele, ranging from academia, government, law, life sciences, and healthcare. Some of its most trusted brands include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor®, and Techstreet™. These brands offer specialized services such as scientific and academic research, patent analytics, pharmaceutical and biotech intelligence, and IP management. Researchers and organizations globally rely on Clarivate's curated knowledge bases to accelerate innovation and bring new ideas to market more efficiently.
Recently, Clarivate has been recognized for its ongoing efforts and achievements. The company has made significant strides in the realm of cancer treatment research, particularly in the area of CAR T-cell therapies. According to a three-part report published by BioWorld™, Clarivate is exploring the rapid pipeline growth and clinical trials in CAR T therapy development in China. This report is part of the company’s commitment to providing valuable insights into groundbreaking treatments and their potential market impacts.
Additionally, Clarivate has launched key updates to its Cortellis CMC Intelligence™ solution, introducing a new post-approval variations module. This update assists pharmaceutical, biotech, and generics companies in streamlining regulatory tracking and optimizing lifecycle management for both small molecules and biologics.
The company also introduced Epidemiology Intelligence™, combining epidemiological data with U.S. claims-based population insights to help biopharma companies accurately gauge market size and target patient demographics. Another significant launch was the Trademark Watch Analyzer, an AI-enhanced trademark protection solution providing faster and more accurate answers to critical business questions by leveraging global trademark and case law data.
Financially, Clarivate reported a slight decrease in revenues for the first quarter of 2024, yet showed resilience and strategic focus on long-term growth. The company continues to invest in product development and operational initiatives to drive future organic revenue growth. Their financial stability is underscored by substantial cash flow and a clear strategy for debt management.
Clarivate’s strategic partnerships, such as the recent collaboration with HealthWise Data, further enhance its offerings by integrating Social Determinants of Health (SDoH) attributes into its Real-World Data repository, contributing to enhanced patient outcomes and healthcare equity.
For more information about Clarivate, its products, and services, visit www.clarivate.com.
Clarivate Plc (NYSE:CLVT) released a new report detailing the evolving trademark landscape influenced by technological advancements like NFTs, metaverse, and cryptocurrency. Key findings reveal a nearly 9,000% increase in NFT-related trademark applications since 2018, with Class 9 filings rising to the second position globally in 2021. Despite overall growth in trademark filings for the 10th consecutive year, filings in Class 10 decreased by 22%. The report emphasizes the significance of intellectual property management in a competitive digital market.
Clarivate Plc (NYSE: CLVT) announced it will report its first quarter 2022 financial results on May 9, 2022, before market opens. Investors can access the press release and earnings supplement on the company's investor website at ir.clarivate.com.
A conference call and webcast will take place on the same day at 9:00 AM Eastern Time to discuss the results. Interested parties can join via phone or through the webcast link provided. An audio replay will be available shortly after the call, accessible until May 23, 2022.
Clarivate Plc (NYSE: CLVT) has announced the winners of its 2021 Revenue Cycle Awards, recognizing healthcare organizations for outstanding performance in revenue cycle KPIs. Winners include Liberty Hospital, four Ardent Health Services hospitals, University of Iowa Hospitals & Clinics, and Novant Health. These organizations showcased resilience amid challenges from the COVID-19 pandemic, improving efficiency and patient experience. Key achievements were noted in metrics like collection rates, billing accuracy, and staff engagement. The awards program aims to highlight exemplary revenue cycle management in the healthcare sector.
Clarivate Plc (NYSE:CLVT) announces the launch of a Global Research Report detailing the research landscape in eleven Central European countries. The report highlights a strong growth in research output, with these nations producing approximately 4% of global papers from 2016 to 2020, a doubling since 1990. Notably, Estonia and Latvia exhibit high international collaboration rates, reaching around 70%. The findings suggest that EU accession has positively influenced research funding and output.
Clarivate Plc (NYSE: CLVT) has launched a resource center to support displaced researchers from Ukraine. This initiative includes over 200 ProQuest Books available freely, a program ensuring continued access to the Web of Science for Ukrainian institutions, and the RapidILL interlibrary loan system for academic resources. This follows Clarivate's decision to cease commercial activities in Russia. The resource center aims to enhance knowledge and understanding of Ukraine while providing critical support for research and discovery.
Clarivate Plc (NYSE: CLVT) has released a report titled Walking the talk on patient centricity, highlighting the importance of personalized patient engagement in life sciences. The report identifies four pillars essential for achieving patient centricity: data inputs, patient involvement, a customer experience approach, and a real-world mindset. It stresses the urgency for life science companies to adapt to this trend for better drug and service outcomes, particularly post-COVID-19. Understanding patient needs is crucial for driving value for both patients and investors.
Clarivate Plc (NYSE: CLVT) released its Biopharma Deals in Review report, showcasing the significant trends in biopharma deal-making for 2021. The report highlights a record 1,968 deals valued at $213.6 billion, with substantial investments in RNA, gene therapies, AI, and oncology. US biotech companies led global capital raising, accounting for 67% of all funds. Notably, oncology deals represented 29% of transactions, with several exceeding $1 billion. This analysis emphasizes the evolving landscape and the growing interest in innovative therapies.
Clarivate Plc (NYSE: CLVT), a global leader in innovation insights, announced its participation in the Bank of America 2022 Information Services Conference. Jerre Stead, Executive Chair and CEO, along with CFO Jonathan Collins, will present on March 17, 2022, at 8:55 AM Eastern Time. A live webcast of the presentation will be accessible via the company's Investor Relations page, with a replay available for 30 days post-event. Clarivate is committed to accelerating innovation and solving complex problems in science and intellectual property.
Clarivate reported strong financial results for Q4 and full year 2021, with revenues of $560.7 million for Q4 (up 23.1%) and $1.88 billion for the year (up 49.7%). Adjusted Net Income soared 20.4% in Q4, reaching $163.2 million, while for the year, it hit $481.7 million, a 66.6% increase. Subscription revenues rose 25.4% in Q4, driven by the ProQuest acquisition. However, the company faced a net loss of $130.4 million in Q4, reflecting a significant increase from the prior year, primarily due to higher interest expenses and warrant adjustments.
Clarivate Plc (NYSE: CLVT) announced it will release its financial results for Q4 and the full year 2021 on March 10, 2022, prior to market opening. The earnings supplement will be available on its investor website at ir.clarivate.com. A conference call and webcast will be held on the same day at 9:00 AM Eastern Time to discuss the results. Investors can join the live audio broadcast by calling specific numbers for the US, Canada, and international participants. A replay will be accessible until March 23, 2022.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
What does Clarivate do?
What are some of Clarivate’s trusted brands?
Where is Clarivate headquartered?
How did Clarivate become an independent company?
When did Clarivate go public?
What recent advancements has Clarivate made in the field of cancer treatment?
What is Cortellis CMC Intelligence™?
What is Epidemiology Intelligence™?
What is the purpose of the Trademark Watch Analyzer?
How does Clarivate enhance patient outcomes with HealthWise Data?
